Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 10/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402071 | 1.00 | MDM2 (0.49) | MDM2FPR2MDM4TP53CASP3 | |
| SCHEMBL14039181 | 0.88 | MDM2 (0.62) | MDM2FPR2MDM4TP53CASP3 | |
| SCHEMBL3728072 | 0.88 | MDM2 (0.62) | MDM2FPR2MDM4TP53CASP3 | |
| SCHEMBL29401511 | 0.88 | MDM2 (0.62) | MDM2FPR2MDM4TP53CASP3 | |
| SCHEMBL29445607 | 0.88 | MDM2 (0.62) | MDM2FPR2MDM4TP53CASP3 | |
| SCHEMBL2307978 | 0.88 | MDM2 (0.62) | MDM2FPR2MDM4TP53CASP3 | |
| SCHEMBL25356445 | 0.87 | MDM4 (0.51) | MDM2FPR2MDM4TP53CASP3 | |
| SCHEMBL25356446 | 0.87 | MDM4 (0.51) | MDM2FPR2MDM4TP53CASP3 | |
| SCHEMBL23421399 | 0.86 | MDM4 (0.52) | MDM2FPR2MDM4TP53CASP3 | |
| SCHEMBL23421400 | 0.86 | MDM4 (0.52) | MDM2FPR2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332495-B2 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | RK Pharma Solutions LLC (US) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332495-B2 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | PEPD, DNPEP, PREP | MDM2 29/4885FPR2 2410/4885MDM4 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.